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SESSION II
ARTHRITIS/OSTEOPORISIS
ARTHRITIS—Clinical Outcomes Studies
PAR1
TREATMENT ADHERENCE WITH TNF-
INHIBITORS AND METHOTREXATE IN
PATIENTS WITH RHEUMATOID ARTHRITIS IN A
LARGE STATE MEDICAID PROGRAM
Singh G1, Mithal A2, Kavanaugh A3
1Stanford University, Palo Alto, CA, USA; 2Institute for Clinical
Outcomes Research and Education, Woodside, CA, USA;
3UCSD, La Jolla, CA, USA
TNF inhibitors signiﬁcantly reduce disease activity and
morbidity in patients with RA, but there are few studies
on the use of these drugs in actual clinical practice.
OBJECTIVES: To evaluate treatment adherence with
TNF inhibitors and methotrexate in patients with
rheumatoid arthritis. METHODS: We studied new drug
starts with TNF inhibitors and methotrexate in RA
patients enrolled in the California Medicaid program for
the period 1999–2002. Drug discontinuation was deﬁned
if there was no prescription reﬁll for 2 consecutive pre-
scription periods (60 days for methotrexate and etaner-
cept and 16 weeks for inﬂiximab). Treatment persistence
was assessed in terms of the number of days of continu-
ous therapy. RESULTS: A total of 77,757 patients had 
a diagnosis of RA during 1999–2002. Of these, 8224
patients had a new drug start on methotrexate, and 2700
on TNF inhibitors (1251 for inﬂiximab and 1449 for
etanercept). Patients on TNF inhibitors were more likely
to be female and non-white. During the study period
(1999–2002), 82.3% of patients who started on
methotrexate switched or discontinued their therapy, 
or added another drug (TNF inhibitor or leﬂunomide).
Of the 2700 new drug starts on TNF inhibitors, 1649
patients (61.1%) discontinued or switched therapy
(78.1% for etanercept, 41.3% for inﬂiximab, p < 0.001
compared to methotrexate). The time to discontinuation
was signiﬁcantly higher in patients on TNF inhibitors
(460.7 + 10.4 days) compared to those on methotrexate
(364.5 + 4.5 days). Cox proportional hazard model
analysis showed that after adjusting for age, gender and
ethnic origin, the treatment discontinuation was still sta-
tistically signiﬁcantly different between the two groups 
(p < 0.001). CONCLUSIONS: RA patients started on
TNF inhibitors tend to stay signiﬁcantly longer on
therapy and have a lower rate of discontinuation com-
pared to those started on methotrexate, perhaps indicat-
ing a better effectiveness/toxicity trade-off.
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TOWARDS VALUING PREFERENCES FOR
DISTRIBUTION OF HEALTH GAIN IN HIP AND
KNEE DISEASE
Payne K, Davies LM, Fargher E
Manchester University, Manchester, Gtr. Manchester, United
Kingdom
OBJECTIVES: To identify key attributes perceived as
important components of decisions to seek, provide or
prioritise treatment for hip and knee disease and assess
whether equity weights that value preferences for the dis-
tribution of health gain should be included in economic
evaluation of joint replacement in the UK. METHODS:
Face-to-face semi-structured interviews were used to iden-
tify factors that are or should be important in the deci-
sions to seek or provide joint replacement surgery. The
study sample comprised 18 patients with hip or knee
disease, 4 general practitioners, 5 hospital clinicians and
6 support staff. A thematic framework approach was
used to identify the key attributes affecting access to treat-
ments and distribution of health gain. A sample of 25
University staff was asked to rank the factors according
to whether they should inﬂuence treatment decisions to
provide joint replacement. RESULTS: Respondents inter-
viewed identiﬁed 17 factors they believed did inﬂuence
treatment decisions. These were ranked according to
whether they should inﬂuence treatment decisions. The
factors and% of respondents who thought they should be
included in the decision making process were: pain
(100%), mobility (100%), potential to beneﬁt (92%),
able to return to normal activities (84%), number of years
in pain (84%), presence of other diseases (72%), patient
cares for another (64%), age (56%), weight (52%), takes
control of own health (44%), cost (28%), type of job
(28%), type of accommodation (28%), healthy lifestyle
(24%), demanding personality (4%), postal address (0%)
and ethnic class (0%). CONCLUSIONS: The results indi-
cate that respondents felt severity of illness and potential
for health gain should be the most important factors for
treatment decisions. However, other factors concerning
the distribution of health gain and access were considered
important, indicating that equity weights are valid com-
ponents of instruments to value preferences for joint
replacement in the UK.
ARTHRITIS—Cost Studies
PAR3
EVALUATING THE IMPACT OF
REIMBURSEMENT OF NON SELECTIVE COX2
INHIBITORS ON TOTAL DISPENSING OF
SELECTED NSAID AND SELECTED DRUGS FOR
ACID RELATED DISORDERS
Trindade R, Lourenço A
INFARMED, Lisbon, Portugal
OBJECTIVE: To evaluate the NHS consumption evolu-
tion for non selective Cox2 inhibitors (NSAID) and Drugs
